Skip to content
Search

Latest Stories

University of Leicester launches MPharm programme to tackle UK’s pharmacist shortage

University of Leicester launches MPharm programme to tackle UK’s pharmacist shortage

Jobs in pharmacy sector are likely to grow by almost 7% by 2027, creating new 4,700 jobs

The University of Leicester has launched a four-year Master of Pharmacy (MPharm) programme to help bridge the nation’s skills gap, and address challenges in the National Health Service (NHS).


Acknowledging the pharmacist workforce crisis, the UK government last year unveiled ‘NHS Long-Term Workforce Plan’ with an aim to increase the training places for pharmacists to around 5,000 places by 2031/32.

The 2022 Community Pharmacy Workforce Survey published by NHS England also reported an increase in the vacancy rate for all roles in the sector, including pharmacy technicians (20 per cent), pharmacists (16 per cent) and dispensing assistants (nine per cent).

While there was a 15 per cent decline in employed pharmacists, use of locum pharmacists increased by 26 per cent.

According to the UK Government’s labour market data, jobs in pharmacy sector are likely to grow by almost seven per cent by 2027, leading to 4,700 new jobs. In the same period, over 52 per cent of the workforce is projected to retire, creating 35,600 job openings.

Professor David Wright, Head of the School of Healthcare at the University, commented: “With a rise in people accessing the ever-growing range of pharmacy services and the projected number of new job openings in the profession, it’s clear to see the UK is in dire need of newly qualified pharmacists.

“Given the need for more pharmacists who can take responsibility for aspects of patient care, including the prescribing of medicines, we have worked quickly and closely with patients, carers and employers to design a new and innovative MPharm programme at Leicester.”

The programme, which will start from autumn 2024, will be led by pharmacists and delivered by pharmacists.

"Students will be surrounded by professional role models who will not only deliver knowledge and know-how but also guide them through to becoming safe and caring healthcare professionals," Professor Wright added.

Students will be offered placements across a range of settings with pharmacy teams across the Midlands, including in community pharmacies, hospitals and GP surgeries.

This course is provisionally accredited by the General Pharmaceutical Council (GPhC), meaning successful graduates can enter Foundation Year training and then become a registered pharmacist.

The University is working towards full accreditation, which is the standard procedure for a new MPharm degree.

From September 2024, the University of Bath is also making its MPharm programme available at the University of Plymouth.

The two universities have collaborated with NHS England to expand the MPharm programme to address community pharmacist workforce shortages, particularly in the south west of England.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less